These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1922654

  • 41. Neuroprotectant drugs in cisplatin neurotoxicity.
    Cavaletti G, Cascinu S, Venturino P, Tedeschi M, Tredici G.
    Anticancer Res; 1996; 16(5B):3149-59. PubMed ID: 8920783
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 45. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
    Gandara DR, Perez EA, Weibe V, De Gregorio MW.
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
    Nishimura G, Horiuchi C, Yoshida T, Kawakami M, Yabuki K, Taguchi T, Nagao J, Kondo N, Masuda Y, Matsuda H, Mikami Y, Tsukuda M.
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
    [Abstract] [Full Text] [Related]

  • 48. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
    Yogi S, Ikeuchi T, Kai Y.
    Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
    [Abstract] [Full Text] [Related]

  • 49. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity.
    Chirino YI, Pedraza-Chaverri J.
    Exp Toxicol Pathol; 2009 May; 61(3):223-42. PubMed ID: 18986801
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Quantification of sodium thiosulphate protection on cisplatin-induced toxicities.
    Leitao DJ, Blakley BW.
    J Otolaryngol; 2003 Jun; 32(3):146-50. PubMed ID: 12921131
    [Abstract] [Full Text] [Related]

  • 52. Cisplatin: process and future.
    Stathopoulos GP.
    J BUON; 2013 Jun; 18(3):564-9. PubMed ID: 24065465
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. [Protecting kidneys from radiocontrast toxicity--do fluids or drugs help?].
    Aitio ML.
    Duodecim; 1999 Jun; 115(19):2075-84. PubMed ID: 11941801
    [No Abstract] [Full Text] [Related]

  • 60. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
    Matsuoka A, Ando Y.
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):200-203. PubMed ID: 28292990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.